A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, Tia A Tummino, Ruth Hüttenhain, Robyn M Kaake, Alicia L Richards, Beril Tutuncuoglu, Helene Foussard, Jyoti Batra, Kelsey Haas, Maya Modak, Minkyu Kim, Paige Haas, Benjamin J Polacco, Hannes Braberg, Jacqueline M Fabius, Manon Eckhardt, Margaret Soucheray, Melanie J Bennett, Merve Cakir, Michael J McGregor, Qiongyu Li, Bjoern Meyer, Ferdinand Roesch, Thomas Vallet, Alice Mac Kain, Lisa Miorin, Elena Moreno, Zun Zar Chi Naing, Yuan Zhou, Shiming Peng, Ying Shi, Ziyang Zhang, Wenqi Shen, Ilsa T Kirby, James E Melnyk, John S Chorba, Kevin Lou, Shizhong A Dai, Inigo Barrio-Hernandez, Danish Memon, Claudia Hernandez-Armenta, Jiankun Lyu, Christopher J P Mathy, Tina Perica, Kala Bharath Pilla, Sai J Ganesan, Daniel J Saltzberg, Ramachandran Rakesh, Xi Liu, Sara B Rosenthal, Lorenzo Calviello, Srivats Venkataramanan, Jose Liboy-Lugo, Yizhu Lin, Xi-Ping Huang, YongFeng Liu, Stephanie A Wankowicz, Markus Bohn, Maliheh Safari, Fatima S Ugur, Cassandra Koh, Nastaran Sadat Savar, Quang Dinh Tran, Djoshkun Shengjuler, Sabrina J Fletcher, Michael C O'Neal, Yiming Cai, Jason C J Chang, David J Broadhurst, Saker Klippsten, Phillip P Sharp, Nicole A Wenzell, Duygu Kuzuoglu-Ozturk, Hao-Yuan Wang, Raphael Trenker, Janet M Young, Devin A Cavero, Joseph Hiatt, Theodore L Roth, Ujjwal Rathore, Advait Subramanian, Julia Noack, Mathieu Hubert, Robert M Stroud, Alan D Frankel, Oren S Rosenberg, Kliment A Verba, David A Agard, Melanie Ott, Michael Emerman, Natalia Jura, Mark von Zastrow, Eric Verdin, Alan Ashworth, Olivier Schwartz, Christophe d'Enfert, Shaeri Mukherjee, Matt Jacobson, Harmit S Malik, Danica G Fujimori, Trey Ideker, Charles S Craik, Stephen N Floor, James S Fraser, John D Gross, Andrej Sali, Bryan L Roth, Davide Ruggero, Jack Taunton, Tanja Kortemme, Pedro Beltrao, Marco Vignuzzi, Adolfo García-Sastre, Kevan M Shokat, Brian K Shoichet, Nevan J Krogan, David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, Tia A Tummino, Ruth Hüttenhain, Robyn M Kaake, Alicia L Richards, Beril Tutuncuoglu, Helene Foussard, Jyoti Batra, Kelsey Haas, Maya Modak, Minkyu Kim, Paige Haas, Benjamin J Polacco, Hannes Braberg, Jacqueline M Fabius, Manon Eckhardt, Margaret Soucheray, Melanie J Bennett, Merve Cakir, Michael J McGregor, Qiongyu Li, Bjoern Meyer, Ferdinand Roesch, Thomas Vallet, Alice Mac Kain, Lisa Miorin, Elena Moreno, Zun Zar Chi Naing, Yuan Zhou, Shiming Peng, Ying Shi, Ziyang Zhang, Wenqi Shen, Ilsa T Kirby, James E Melnyk, John S Chorba, Kevin Lou, Shizhong A Dai, Inigo Barrio-Hernandez, Danish Memon, Claudia Hernandez-Armenta, Jiankun Lyu, Christopher J P Mathy, Tina Perica, Kala Bharath Pilla, Sai J Ganesan, Daniel J Saltzberg, Ramachandran Rakesh, Xi Liu, Sara B Rosenthal, Lorenzo Calviello, Srivats Venkataramanan, Jose Liboy-Lugo, Yizhu Lin, Xi-Ping Huang, YongFeng Liu, Stephanie A Wankowicz, Markus Bohn, Maliheh Safari, Fatima S Ugur, Cassandra Koh, Nastaran Sadat Savar, Quang Dinh Tran, Djoshkun Shengjuler, Sabrina J Fletcher, Michael C O'Neal, Yiming Cai, Jason C J Chang, David J Broadhurst, Saker Klippsten, Phillip P Sharp, Nicole A Wenzell, Duygu Kuzuoglu-Ozturk, Hao-Yuan Wang, Raphael Trenker, Janet M Young, Devin A Cavero, Joseph Hiatt, Theodore L Roth, Ujjwal Rathore, Advait Subramanian, Julia Noack, Mathieu Hubert, Robert M Stroud, Alan D Frankel, Oren S Rosenberg, Kliment A Verba, David A Agard, Melanie Ott, Michael Emerman, Natalia Jura, Mark von Zastrow, Eric Verdin, Alan Ashworth, Olivier Schwartz, Christophe d'Enfert, Shaeri Mukherjee, Matt Jacobson, Harmit S Malik, Danica G Fujimori, Trey Ideker, Charles S Craik, Stephen N Floor, James S Fraser, John D Gross, Andrej Sali, Bryan L Roth, Davide Ruggero, Jack Taunton, Tanja Kortemme, Pedro Beltrao, Marco Vignuzzi, Adolfo García-Sastre, Kevan M Shokat, Brian K Shoichet, Nevan J Krogan
Abstract
A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
Figures
References
- Wu F et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
- Novel Coronavirus (2019-nCoV) situation reports. .
- Wang C, Horby PW, Hayden FG & Gao GF A novel coronavirus outbreak of global health concern. The Lancet vol. 395 470–473 (2020).
- Zhu N et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
- Su S et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 24, 490–502 (2016).
- Gates B Responding to Covid-19 — A Once-in-a-Century Pandemic? New England Journal of Medicine (2020) doi:10.1056/nejmp2003762.
- Sheahan TP et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).
- Sheahan TP et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus. bioRxiv 2020.03.19.997890 (2020) doi:10.1101/2020.03.19.997890.
- Paton J Moderna’s Coronavirus Vaccine Trial Set to Begin This Month. Bloomberg News (2020).
- Hoffmann M et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020) doi:10.1016/j.cell.2020.02.052.
- Prussia A, Thepchatri P, Snyder JP & Plemper RK Systematic approaches towards the development of host-directed antiviral therapeutics. Int. J. Mol. Sci. 12, 4027–4052 (2011).
- Chan JF-W et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9, 221–236 (2020).
- Fehr AR & Perlman S Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1–23 (2015).
- Teo G et al. SAINTexpress: improvements and additional features in Significance Analysis of INTeractome software. J. Proteomics 100, 37–43 (2014).
- Jäger S et al. Global landscape of HIV-human protein complexes. Nature 481, 365–370 (2012).
- Bojkova D et al. SARS-CoV-2 infected host cell proteomics reveal potential therapy targets. In Review (2020).
- Eckhardt M, Hultquist JF, Kaake RM, Hüttenhain R & Krogan NJ A systems approach to infectious disease. Nat. Rev. Genet. (2020) doi:10.1038/s41576-020-0212-5.
- Harcourt J et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States. Emerg. Infect. Dis. 26, (2020).
- Wang D et al. A deep proteome and transcriptome abundance atlas of 29 healthy human tissues. Mol. Syst. Biol. 15, e8503 (2019).
- Li M et al. Identification of antiviral roles for the exon-junction complex and nonsense-mediated decay in flaviviral infection. Nat Microbiol (2019) doi:10.1038/s41564-019-0375-z.
- Penn BH et al. An Mtb-Human Protein-Protein Interaction Map Identifies a Switch between Host Antiviral and Antibacterial Responses. Mol. Cell 71, 637–648.e5 (2018).
- Barnes PJ Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 71, 451–464 (2009).
- Xu P et al. NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2. J. Exp. Clin. Cancer Res. 38, 483 (2019).
- Dewe JM, Fuller BL, Lentini JM, Kellner SM & Fu D TRMT1-Catalyzed tRNA Modifications Are Required for Redox Homeostasis To Ensure Proper Cellular Proliferation and Oxidative Stress Survival. Mol. Cell. Biol. 37, (2017).
- Kondo T, Watanabe M & Hatakeyama S TRIM59 interacts with ECSIT and negatively regulates NF-κB and IRF-3/7-mediated signal pathways. Biochem. Biophys. Res. Commun. 422, 501–507 (2012).
- Li S, Wang L, Berman M, Kong Y-Y & Dorf ME Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 35, 426–440 (2011).
- Faria PA et al. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol. Cell 17, 93–102 (2005).
- Slaine PD, Kleer M, Smith NK, Khaperskyy DA & McCormick C Stress Granule-Inducing Eukaryotic Translation Initiation Factor 4A Inhibitors Block Influenza A Virus Replication. Viruses 9, (2017).
- Reineke LC et al. Casein Kinase 2 Is Linked to Stress Granule Dynamics through Phosphorylation of the Stress Granule Nucleating Protein G3BP1. Mol. Cell. Biol. 37, (2017).
- Kindrachuk J et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob. Agents Chemother. 59, 1088–1099 (2015).
- Timms RT et al. A glycine-specific N-degron pathway mediates the quality control of protein N-myristoylation. Science 365, (2019).
- Quan B, Seo H-S, Blobel G & Ren Y Vesiculoviral matrix (M) protein occupies nucleic acid binding site at nucleoporin pair (Rae1 • Nup98). Proc. Natl. Acad. Sci. U. S. A. 111, 9127–9132 (2014).
- Frieman M et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 81, 9812–9824 (2007).
- Nakagawa K, Narayanan K, Wada M & Makino S Inhibition of Stress Granule Formation by Middle East Respiratory Syndrome Coronavirus 4a Accessory Protein Facilitates Viral Translation, Leading to Efficient Virus Replication. J. Virol. 92, (2018).
- Raaben M, Groot Koerkamp MJA, Rottier PJM & de Haan CAM Mouse hepatitis coronavirus replication induces host translational shutoff and mRNA decay, with concomitant formation of stress granules and processing bodies. Cell. Microbiol. 9, 2218–2229 (2007).
- Ivanov P, Kedersha N & Anderson P Stress Granules and Processing Bodies in Translational Control. Cold Spring Harb. Perspect. Biol. 11, (2019).
- Thompson PA et al. Abstract 2698: eFT226, a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma. Experimental and Molecular Therapeutics (2019) doi:10.1158/1538-7445.am2019-2698.
- Nakagawa K, Lokugamage KG & Makino S Viral and Cellular mRNA Translation in Coronavirus-Infected Cells. Adv. Virus Res. 96, 165–192 (2016).
- Müller C et al. Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Res. 150, 123–129 (2018).
- Cencic R et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J. Virol. 85, 6381–6389 (2011).
- Knoops K et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 6, e226 (2008).
- Shah PS et al. Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis. Cell 175, 1931–1945.e18 (2018).
- Heaton NS et al. Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity 44, 46–58 (2016).
- Mahon C, Krogan NJ, Craik CS & Pick E Cullin E3 ligases and their rewiring by viral factors. Biomolecules 4, 897–930 (2014).
- Soucy TA et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736 (2009).
- Faivre EJ et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature 578, 306–310 (2020).
- Filippakopoulos P et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214–231 (2012).
- Marazzi I et al. Suppression of the antiviral response by an influenza histone mimic. Nature 483, 428–433 (2012).
- Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease - Full Text View - . .
- Carelli JD et al. Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex. Elife 4, (2015).
- Spicka I et al. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. Ann. Hematol. 98, 2139–2150 (2019).
- Mitsuda T et al. Sigma-1Rs are upregulated via PERK/eIF2α/ATF4 pathway and execute protective function in ER stress. Biochem. Biophys. Res. Commun. 415, 519–525 (2011).
- Si L et al. Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics. bioRxiv 2020.04.13.039917 (2020) doi:10.1101/2020.04.13.039917.
- Riva L et al. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. bioRxiv 2020.04.16.044016 (2020) doi:10.1101/2020.04.16.044016.
- White NJ Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 7, 549–558 (2007).
- Armstrong JF et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. Nucleic Acids Res. 48, D1006–D1021 (2020).
- Yang D & Leibowitz JL The structure and functions of coronavirus genomic 3’ and 5’ ends. Virus Res. 206, 120–133 (2015).
- Yang H et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U. S. A. 100, 13190–13195 (2003).
- Thiel V et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84, 2305–2315 (2003).
- Xie Y et al. GPS-Lipid: a robust tool for the prediction of multiple lipid modification sites. Sci. Rep. 6, 28249 (2016).
- Ren J et al. CSS-Palm 2.0: an updated software for palmitoylation sites prediction. Protein Eng. Des. Sel. 21, 639–644 (2008).
- Krogh A, Larsson B, von Heijne G & Sonnhammer EL Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol. 305, 567–580 (2001).
- Almagro Armenteros JJ et al. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat. Biotechnol. 37, 420–423 (2019).
- Chiva C et al. QCloud: A cloud-based quality control system for mass spectrometry-based proteomics laboratories. PLoS One 13, e0189209 (2018).
- Cox J & Mann M MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
- Cox J et al. Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ. Mol. Cell. Proteomics 13, 2513–2526 (2014).
- Verschueren E et al. Scoring Large-Scale Affinity Purification Mass Spectrometry Datasets with MiST. Curr. Protoc. Bioinformatics 49, 8.19.1–16 (2015).
- Giurgiu M et al. CORUM: the comprehensive resource of mammalian protein complexes-2019. Nucleic Acids Res. 47, D559–D563 (2019).
- Shannon P et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
- Huttlin EL et al. The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 162, 425–440 (2015).
- Vizcaíno JA et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223–226 (2014).
- Deutsch EW et al. The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 45, D1100–D1106 (2017).
- Chaudhury S, Lyskov S & Gray JJ PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics 26, 689–691 (2010).
- Joosten RP, Long F, Murshudov GN & Perrakis A The PDB_REDO server for macromolecular structure model optimization. IUCrJ 1, 213–220 (2014).
- Drozdetskiy A, Cole C, Procter J & Barton GJ JPred4: a protein secondary structure prediction server. Nucleic Acids Res. 43, W389–94 (2015).
- Sievers F et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
- Gaulton A et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017).
- Sterling T & Irwin JJ ZINC 15--Ligand Discovery for Everyone. J. Chem. Inf. Model. 55, 2324–2337 (2015).
- Schmidt HR, Betz RM, Dror RO & Kruse AC Structural basis for σ receptor ligand recognition. Nat. Struct. Mol. Biol. 25, 981–987 (2018).
- Mysinger MM & Shoichet BK Rapid context-dependent ligand desolvation in molecular docking. J. Chem. Inf. Model. 50, 1561–1573 (2010).
- Chu DKW et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin. Chem. 66, 549–555 (2020).
- Huang X-P, Mangano T, Hufeisen S, Setola V & Roth BL Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev. Technol. 8, 727–742 (2010).
- Besnard J et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215–220 (2012).
Source: PubMed